Drug delivery approaches for breast cancer

Singh, Santosh Kumar; Singh, S. P.; Lillard, James W.; Singh, Rajesh

doi:10.2147/ijn.s140325

Cited by 178 publications

(109 citation statements)

References 105 publications

Supporting

Mentioning

106

Contrasting

Unclassified

Order By: Relevance

“…Tremendous efforts have been made in discovering and synthesizing inhibitors for efflux pumps to re-sensitize resistant cancer cells to chemotherapeutic drugs. One of the few strategies that were successful in inhibiting the active efflux of ABC transporters is the encapsulation of drugs with nanoparticles [30, 38, 39]. In the present study, we, interestingly, found that the combined treatment inhibited the growth of the DTX resistant PC3 cells by down-regulating the ABCB1, ABCC1 and ABCG2 genes at both protein and mRNA levels.…”

Section: Discussionsupporting

confidence: 55%

Reversal of drug resistance by planetary ball milled (PBM) nanoparticle loaded with resveratrol and docetaxel in prostate cancer

2018

Self Cite

View full text Add to dashboard Cite

The folate receptor (FR) is a valued target that is highly expressed in various cancers, which will expedite the development of ligand-receptor binding based cancer therapeutics. In the present investigation, through tissue microarray analysis, we report higher levels of folate receptor expression in prostate cancer (PCa) tissue derived from patients, which were minimal in normal tissue. For folate-receptor based targeted therapy of PCa, we generated novel planetary ball milled (PBM) nanoparticles (NPs) encapsulated with resveratrol (RES), and in combination with docetaxel (DTX) and conjugated with folic acid (FA) on the surface. The cytotoxic effect of FA-conjugated DTX-nanoparticles was found effectual that reduced the concentration of free drug (DTX) to 28 times. Flow cytometry analysis showed a significant increase in the number of apoptotic cells by 30.92% and 65.9% in the FA-conjugated RES and in combination with DTX nanoparticle formulation respectively. However, only 8.9% apoptotic cells were found with control (empty NP). The expressions of NF-kB p65, COX-2, pro (BAX, BAK) and anti-apoptotic (BCL-2, BCL-XL) genes were significantly reduced after treatment with FA-RES + DTX-NP. In addition, the FA-conjugated DTX formulation exhibited additional cytotoxic effects with the down-regulation of survivin and an increased expression of Cleaved Caspase-3 in PCa cells. Further, we observed that treating DTX resistant PCa cells with FA-RES + DTX-NP exhibited a reversal of the ABC-transporter markers thereby limiting the multidrug resistance phenotype of the cancer cells. Our results strongly suggested that FA conjugated nanoparticle drugs acted as effective inhibitors of drug efflux that effectually enhances the intracellular concentration of the drug to exhibit their cytotoxic effect.

show abstract

Section: Discussionsupporting

confidence: 55%

Reversal of drug resistance by planetary ball milled (PBM) nanoparticle loaded with resveratrol and docetaxel in prostate cancer

2018

Self Cite

View full text Add to dashboard Cite

show abstract

“…The controlled release of drugs to a precise site of a disease using a nanocarrier vehicle increases their therapeutic efficiency . Carbon‐based nanomaterials are potential candidates for various applications in medicine generally and anticancer therapy, in particular.…”

Section: Resultsmentioning

confidence: 99%

“…Tumor pathophysiology manifests with characteristic changes such as in pH, enzyme activity, or redox properties . Controlled ‐ release delivery systems based on nanotransporters delivering a bioactive agent to the target site at a controlled concentration could increase the therapeutic efficiency of the drugs .…”

Section: Resultsmentioning

confidence: 99%

Fullerene as a doxorubicin nanotransporter for targeted breast cancer therapy: Capillary electrophoresis analysis

2018

View full text Add to dashboard Cite

The clinical use of doxorubicin (DOX) is limited by dose-related cardiomyopathy, which becomes more prevalent with increasing cumulative doses of the drug. Complexes of fullerene with DOX were designed and studied using biophysical methods. The ability of DOX to release from fullerene at different pHs was analyzed. It has been shown that the size of the fullerene-DOX complexes was ∼280 nm. The zeta potential for fullerene was -30 mV, for DOX -8 mV, and for fullerene-DOX conjugates -24 mV. Drug release was studied by CE with LIF detection. When fullerene-DOX conjugates were separated in a pH 7.5 buffer, 43% of all DOX signals were derived from free DOX, with the signal increasing as pH decreased. At pH 5.25, all DOX had been released and 100% of the signal was derived from free DOX. The release of DOX from complexes with fullerene at lower pH can be used in targeted antineoplastic therapy, resulting in lower toxicity for less acidic non-target tissue.

show abstract

“…Many clinical trials have reported that treatment of HER alone has a low response rate against the extracellular domain of HER-2-positive breast cancer [48][49][50][51]. On the other hand, a combination therapy with chemotherapeutic drugs promotes not only the inhibition of tumor growth, but also the overall survival rate of breast cancer patients [52][53][54][55][56]. To determine the synergistic effect of combination therapy with HER and DOX, the viability of DL-CNPs in SK-BR-3 cells was compared with that in MDA-MB-231 cells.…”

Section: Evaluation Of Active Targeting and Intracellular Accumulatiomentioning

confidence: 99%

Dual pH- and GSH-Responsive Degradable PEGylated Graphene Quantum Dot-Based Nanoparticles for Enhanced HER2-Positive Breast Cancer Therapy

Van

Hong

et al. 2020

Nanomaterials

View full text Add to dashboard Cite

Dual stimuli-responsive degradable carbon-based nanoparticles (DS-CNPs) conjugated with Herceptin (HER) and polyethylene glycol (PEG) have been designed for the treatment of HER2-positive breast cancer. Each component has been linked through disulfide linkages that are sensitive to glutathione in a cancer microenvironment. β-cyclodextrin (β-CD) on the surface of DS-CNPs formed an inclusion complex (DL-CNPs) with doxorubicin (DOX) at a high loading capacity of 5.3 ± 0.4%. In response to a high level of glutathione (GSH) and low pH in a tumor environment, DL-CNPs were rapidly degraded and released DOX in a controlled manner via disruption of host–guest inclusion. These novel DL-CNPs exhibited high cellular uptake with low toxicity, which induced the efficient inhibition of antitumor activity both in vitro and in vivo. Cell viability, confocal laser scanning microscopy, and animal studies indicate that DL-CNPs are a great platform with a synergistically enhanced antitumor effect from the dual delivery of HER and DOX in DL-CNPs.

show abstract

Drug delivery approaches for breast cancer

Cited by 178 publications

References 105 publications

Reversal of drug resistance by planetary ball milled (PBM) nanoparticle loaded with resveratrol and docetaxel in prostate cancer

Reversal of drug resistance by planetary ball milled (PBM) nanoparticle loaded with resveratrol and docetaxel in prostate cancer

Fullerene as a doxorubicin nanotransporter for targeted breast cancer therapy: Capillary electrophoresis analysis

Dual pH- and GSH-Responsive Degradable PEGylated Graphene Quantum Dot-Based Nanoparticles for Enhanced HER2-Positive Breast Cancer Therapy

Contact Info

Product

Resources

About